Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis

Journal of Critical Care

Volumn 26, Issue 6, 2011, Pages 550-555

  Mühl, Diána ^a   Nagy, Bálint ^a   Woth, Gábor ^a   Falusi, Boglárka ^a   Bogár, Lajos ^a   Weber, György ^a   Lantos, János ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Matrix metalloproteinases; Severe sepsis; Tissue inhibitors of metalloproteinases

Indexed keywords

BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITAL ADMISSION; HUMAN; MALE; PROGNOSIS; PROSPECTIVE STUDY; SEPSIS;

CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; SEPSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 81955160877     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2011.02.011     Document Type: Article

References (30)

1. Martin G.S., Mannino D.M., Eaton S., et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554.
2. Linde-Zwirble W.T., Angus D.C. Severe sepsis epidemiology: sampling, selection, and society. Crit Care 2004, 8:222-226.
3. Dellinger R.P. Cardiovascular management of septic shock. Crit Care Med 2003, 31:946-955.
4. Hoffmann U., Brueckmann M., Borggrefe M. Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis?. Crit Care 2009, 13:1006.
5. Woessner J.F. The matrix metalloproteinase family. Matrix Metalloproteinases 1998, 1-14. Academic Press, San Diego. W.C. Parks, R.P. Mecham (Eds.).
6. Hijova E. Matrix metalloproteinases: their biological functions and clinical implications. Bratisl Lek Listy 2005, 106(3):127-132.
7. Lorente L., Martin M.M., Labarta L., et al. Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Crit Care 2009, 13:R158.
8. Longo G.M., Xiong W., Greiner T.C., et al. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002, 110(5):625-632.
9. Brinckerhoff C.E., Matrisian L.M. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002, 3:207-214.
10. Chow A.K., Cena J., Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 2007, 152(2):189-205.
11. Ulrich D., Noah E.M., von Heimburg D., et al. TIMP-1, MMP-2, MMP-9, and PIIINP as serum markers for skin fibrosis in patients following severe burn trauma. Plast Reconst Surg 2003, 111(4):1423-1431.
12. Pennanen H., Kuittinen O., Turpeenniemi-Hujanen T. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma. Eur J Haematol 2008, 80(1):46-54.
13. Galis Z.S., Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis the good, the bad, and the ugly. Circ Res 2002, 90(3):251-262.
14. Elkington P.T., O'Kane C.M., Friedland J.S. The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol 2005, 142:12-20.
15. Opdenakker G.P., Van den Steen H.E., Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 2001, 22:571-579.
16. Hoffmann U., Bertsch T., Dvortsak E., et al. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis. Scand J Infect Dis 2006, 38:867-872.
17. Pugin J., Widmer M.C., Kossodo S., et al. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol 1999, 20:458-464.
18. Chromek M., Tullus K., Lundahl J., et al. Tissue inhibitor of metalloproteinase 1 activates normal human granulocytes, protects them from apoptosis, and blocks their transmigration during inflammation. Infect Immun 2004, 72:82-88.
19. Yassen K.A., Galley H.F., Webster N.R. Matrix metalloproteinase-9 concentrations in critically ill patients. Anaesthesia 2001, 56:729-732.
20. Nakamura T., Ebihara I., Shimada N., et al. Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA levels in patients with septic shock: effect of fiber-immobilized polymyxin B treatment. Am J Med Sci 1998, 316:355-360.
21. Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101(6):1644-1655.
22. Lalu M.M., Csont T., Schulz R. Matrix metalloproteinase activities are altered in the heart and plasma during endotoxemia. Crit Care Med 2004, 32(6):1332-1337.
23. Albert J., Radomski A., Soop A., et al. Differential release of matrix metalloproteinase-9 and nitric oxide following infusion of endotoxin to human volunteers. Acta Anaesthesiol Scand 2003, 47:407-410.
24. Hristov M., Erl W., Weber P.C. Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol 2003, 23(7):1185-1189.
25. Rafat N., Hanusch C., Brinkkoetter P.T., et al. Increased circulating endothelial progenitor cells in septic patients: correlation with survival. Crit Care Med 2007, 35(7):1677-1684. [Erratum in: 1994. JAMA 271(17):1321].
26. Fortuna G.M., Figueiredo-Lopes L., Dias-Junior C.A., et al. A role for matrix metalloproteinase-9 in the hemodynamic changes following acute pulmonary embolism. Int J Cardiol 2007, 114(1):22-27.
27. Cena J.J., Lalu M.M., Cho W.J., et al. Inhibition of matrix metalloproteinase activity in vivo protects against vascular hyporeactivity in endotoxemia. Am J Physiol Heart Circ Physiol 2010, 298(1):H45-H51.
28. Gerlach R.F., Uzuelli J.A., Souza-Tarla C.D., et al. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (mmp)-2 and mmp-9 activities. Anal Biochem 2005, 344:147-149.
29. Ceron C.S., Castro M.M., Rizzi E., et al. Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol 2010, 160(1):77-87.
30. Castro M.M., Rizzi E., Rodrigues G.J., et al. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic Biol Med 2009, 46(9):1298-1307.